Covidien closes enrollment in iliac stent studies

February 21, 2013 by Sony Salzman

Covidien closes enrollment in a pair of clinical trials, Visibility and Durability, examining its iliac stents for treating peripheral artery disease.

YYmeta

Covidien (NYSE:COV) said it closed enrollment in a pair of its Visibility and Durability iliac stent clinical studies.

The prospective, multinational studies are designed to compare balloon stents with self-expanding stents in the iliac arteries for treating peripheral artery disease.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp